Cowen and Company’s Editas Medicine EDIT Stock Holding History

Cowen and Company’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-16,600	Closed	-$138K	–	676
2021 Q3	$138K	Buy	+16,600	New	+$910K	0.01%	285

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Cowen and Company's EDIT Position: Q4 2021 in Review

Cowen and Company sold out of Editas Medicine (EDIT) in Q4 2021, closing a stake of 2,362 shares — an estimated $97K sold.

Cowen and Company first reported a position in EDIT in Q3 2021 and held it in 1 quarter. The position peaked at $97K in Q3 2021. 306 funds tracked by Wall St. Rank hold EDIT as of Q4 2021.

Cowen and Company reported no remaining Editas Medicine position as of Q4 2021 after selling out during the quarter.
Cowen and Company sold 2,362 Editas Medicine shares in Q4 2021, an estimated $97K.
Cowen and Company first reported a position in Editas Medicine in Q3 2021 and held it in 1 quarter.
Cowen and Company's Editas Medicine position peaked at $97K in Q3 2021.
306 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2021.

Based on Cowen and Company's 13F filing for Q4 2021, filed 14 Feb 2022.